Insilico Medicine and China Medical System (CMS) have announced a series of AI‑empowered drug discovery collaborations in the fields of central nervous system and autoimmune diseases.  According to the collaboration agreement, the parties will combine Insilico Medicine's AI-enabled drug discovery and development capabilities with CMS's experienced R&D team and disease-area expertise to advance at least […]